NEW YORK (GenomeWeb) – InSilixa and DNA Software announced today that they have formed a partnership to develop multiplex infectious disease panels for use on InSilixa's complementary metal-oxide semiconductor, or CMOS, biochip platform.
The CMOS technology enables rapid detection and genotyping of pathogens in clinical samples, as well as simultaneous drug-resistance profiling, using highly-multiplexed targeted DNA sequencing, according to InSilixa. The company is focusing its first generation of biochips on point-of-care infectious disease diagnosis.
Under the terms of their deal, the companies will develop the panels using DNA Software's sequence identification algorithms, as well as its PCR and multiplex primer design software.
Additional terms were not disclosed.